UroGen Pharma (NASDAQ:URGN) Rating Reiterated by HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $54.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 301.49% from the stock’s current price.

Separately, Oppenheimer cut their target price on UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating on the stock in a research report on Friday, March 15th.

UroGen Pharma Stock Down 2.9 %

UroGen Pharma stock opened at $13.45 on Monday. The stock has a market cap of $315.40 million, a PE ratio of -3.61 and a beta of 1.09. UroGen Pharma has a 12-month low of $8.69 and a 12-month high of $24.13. The business’s 50-day moving average price is $15.12 and its two-hundred day moving average price is $14.71.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, March 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The business had revenue of $23.53 million during the quarter, compared to analyst estimates of $22.30 million. As a group, analysts expect that UroGen Pharma will post -3.59 earnings per share for the current year.

Insider Activity at UroGen Pharma

In related news, insider Mark Schoenberg sold 12,000 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $14.05, for a total transaction of $168,600.00. Following the sale, the insider now owns 139,437 shares of the company’s stock, valued at approximately $1,959,089.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On UroGen Pharma

Several hedge funds have recently bought and sold shares of URGN. RTW Investments LP lifted its stake in shares of UroGen Pharma by 101.4% in the 4th quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock valued at $25,902,000 after acquiring an additional 869,344 shares during the last quarter. RA Capital Management L.P. purchased a new stake in UroGen Pharma during the 3rd quarter valued at $20,787,000. Silverarc Capital Management LLC bought a new stake in UroGen Pharma in the 3rd quarter worth $7,129,000. Laurion Capital Management LP increased its position in shares of UroGen Pharma by 3.1% in the third quarter. Laurion Capital Management LP now owns 380,600 shares of the company’s stock valued at $5,332,000 after acquiring an additional 11,495 shares during the period. Finally, Superstring Capital Management LP bought a new position in UroGen Pharma during the 4th quarter valued at approximately $3,831,000. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.